ANN HEMATOL 2020 10.1007/s00277-020-04005-6
A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis
Yoon1, SE; Kim, SJ; Yoon, KH; Koh, Y; Mun, YC; Do, YR; Choi, YS; Yang, DH; Kim, MK; Lee, GW; Suh, C; Ko, YH; Kim, WS

ANN HEMATOL 2020 10.1007/s00277-020-04008-3
Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas
Hur1, JY; Kim, YJ; Yoon, SE; Son, DS; Park, WY; Kim, SJ; Park, D; Kim, WS

ANN LAB MED 2020 10.3343/alm.2020.40.3.253
Isolation of Small Extracellular Vesicles From Human Serum Using a Combination of Ultracentrifugation With Polymer-Based Precipitation
Ryu1, KJ; Lee, JY; Park, C; Cho, D; Kim, SJ

ANN HEMATOL 2020 10.1007/s00277-020-04083-6
A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study
Yoon1, SE; Eun, Y; Huh, K; Chung, CR; Yoo, IY; Cho, J; Cho, D; Ko, YH; Park, S; Kim, WS; Kim, SJ

CYTOKINE 2020 10.1016/j.cyto.2020.155048
Pre-treatment serum IL-10 predicts the risk of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma
Yi1, JH; Yoon, SE; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ

Lancet Haematol 2020 10.1016/S2352-3026(19)30283-2
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project
Fox1, CP; Civallero, M; Ko, YH; Manni, M; Skrypets, T; Pileri, S; Kim, SJ; Cabrera, ME; Shustov, AR; Chiattone, CS; Horwitz, SM; Dlouhy, I; Spina, M; Hitz, F; Montoto, S; Nagler, A; Martinez, V; De Souza, CA; Fernandez-Alvarez, R; Ballova, V; Gabus, R; Inghirami, G; Federico, M; Kim, WS

MODERN PATHOL 2020 10.1038/s41379-019-0392-8
Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression
Cho1, J; Kim, SJ; Park, WY; Kim, J; Woo, J; Kim, G; Yoon, SE; Ko, YH; Kim, WS

CANCER RES TREAT 2020 10.4143/crt.2019.198
Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial
Kim1, SJ; Yoon, DH; Kim, JS; Kang, HJ; Lee, HW; Eom, HS; Hong, JY; Cho, J; Ko, YH; Huh, J; Yang, WI; Park, WS; Lee, SS; Suh, C; Kim, WS

INVEST NEW DRUG 2020 10.1007/s10637-020-00916-3
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Kroschinsky1, F; Middeke, JM; Janz, M; Lenz, G; Witzens-Harig, M; Bouabdallah, R; La Rosee, P; Viardot, A; Salles, G; Kim, SJ; Kim, TM; Ottmann, O; Chromik, J; Quinson, AM; von Wangenheim, U; Burkard, U; Berk, A; Schmitz, N

BLOOD ADV 2020 10.1182/bloodadvances.2019001114
Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk
Witalis1, M; Chang, J; Zhong, MC; Bouklouch, Y; Panneton, V; Li, JN; Buch, T; Kim, SJ; Kim, WS; Ko, YH; Veillette, A; Suh, WK

J HEMATOL ONCOL 2020 10.1186/s13045-020-00855-9
Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group
Yoon1, DH; Cao, JN; Chen, TY; Izutsu, K; Kim, SJ; Kwong, YL; Lin, TY; Thye, LS; Xu, B; Yang, DH; Kim, WS

PSYCHO-ONCOL 2020 10.1002/pon.5265
Impact of fear of cancer recurrence on survival among lymphoma patients
Kim1, SJ; Kang, D; Kim, IR; Yoon, SE; Kim, WS; Butow, PN; Guallar, E; Cho, J

J AM COLL CARDIOL 2020 10.1016/j.jacc.2019.11.045
Prognostic Value of the Index of Microcirculatory Resistance Over Serum Biomarkers in Cardiac Amyloidosis
Choi1, KH; Lee, JM; Kim, SR; Kim, D; Choi, JO; Kim, SJ; Kim, K; Kim, JS; Koo, BK; Jeon, ES

ANN HEMATOL 2020 10.1007/s00277-019-03803-x
Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report
Jo1, JC; Kim, SJ; Lee, HS; Eom, HS; Lee, SI; Park, Y; Lee, JO; Lee, Y; Yhim, HY; Yang, DH; Byun, JM; Kang, HJ; Kim, HJ; Shin, HJ; Yoo, KH; Suh, C

BMC CANCER 2020 10.1186/s12885-020-6612-2
Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma
Cho1, I; Lee, H; Yoon, SE; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ

CLIN CANCER RES 2020 10.1158/1078-0432.CCR-19-0694
Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion
Ryu1, D; Kim, SJ; Hong, Y; Jo, A; Kim, N; Kim, HJ; Lee, HO; Kim, K; Park, WY

ANN HEMATOL 2020 10.1007/s00277-019-03891-9
A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma
Won1, YW; Lee, H; Eom, HS; Kim, JS; Suh, C; Yoon, DH; Hong, JY; Kang, HJ; Lee, JH; Kim, WS; Kim, SJ; Lee, WS; Chang, MH; Do, YR; Yi, JH; Kim, I; Won, JH; Kim, K; Oh, SY; Jo, JC

ANN LAB MED 2020 10.3343/alm.2020.40.1.88
Relationship of Circulating Cytomegalovirus Levels Obtained Through Antigenemia Testing and Quantitative PCR Differs Between Children and Adults
Choi1, S; Kim, YJ; Yoo, KH; Sung, KW; Koo, HH; Kim, SJ; Jang, JH; Kim, K; Jung, CW; Huh, HJ; Kang, ES

AM J HEMATOL 2020 10.1002/ajh.25726
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)
Lee1, HS; Kim, K; Kim, SJ; Lee, JJ; Kim, I; Kim, JS; Eom, HS; Yoon, DH; Suh, C; Shin, HJ; Mun, YC; Kim, MK; Lim, SN; Choi, CW; Kang, HJ; Yoon, SS; Min, CK

RESP MED 2020 10.1016/j.rmed.2019.105853
Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors
Im1, Y; Lee, J; Kim, SJ; Koh, WJ; Jhun, BW; Lee, SH

KOREAN JOURNAL OF INTERNAL MEDICINE 2020 10.3904/kjim.2018.196
Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance
Kim1, HK; Kang, W; Sinn, DH; Lee, JH; Kim, WS; Kim, SJ

MEDICINE 2020 10.1097/MD.0000000000018905
Tc-99m-DPD scintigraphy and SPECT/CT in patients with AL and ATTR type amyloidosis Potential clinical implications
Lee1, JH; Kim, K; Choi, JO; Kim, SJ; Jeon, ES; Choi, JY

BONE MARROW TRANSPL 2019 10.1038/s41409-019-0629-7
Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma
Lee1, YJ; Moon, JH; Sohn, SK; Kim, SJ; Jung, SH; Lee, JJ; Jo, JC; Shin, HJ; Lee, WS; Lee, JH; Bae, SH; Kim, MK; Lee, HS; Kim, K; Min, CK

ANN HEMATOL 2019 10.1007/s00277-019-03791-y
Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma
Yi1, JH; Lee, GW; Do, YR; Jung, HR; Hong, JY; Yoon, DH; Suh, C; Choi, YS; Yi, SY; Sohn, BS; Kim, BS; Oh, SY; Park, J; Jo, JC; Lee, SS; Oh, YH; Kim, SJ; Kim, WS

MEDICINE 2019 10.1097/MD.0000000000017641
Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997-2016 An observational study
Sim1, J; Takayama, T; Cho, J; Kim, SJ; Kim, WS; Ree, HJ; Ko, YH

BMC CANCER 2019 10.1186/s12885-019-6303-z
Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma
Kim1, SJ; Yoon, DH; Kang, HJ; Hong, JY; Lee, HS; Oh, SY; Shin, HJ; Kong, JH; Yi, JH; Sakamoto, K; Ko, YH; Huh, J; Lee, SS; Takeuchi, K; Shin, DY; Suh, C; Kim, WS

SCI REP-UK 2019 10.1038/s41598-019-51522-0
A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study
Tan1, KM; Chia, B; Lim, JQ; Khoo, LP; Cheng, CL; Tan, L; Poon, E; Somasundaram, N; Farid, M; Tang, TPL; Tao, M; Cheah, DMZ; Laurensia, Y; Pang, JWL; Song, T; Tan, J; Huang, DC; Kim, SJ; Kim, WS; Ong, CK; Lim, ST; Chan, JY

J CLIN APHERESIS 2019 10.1002/jca.21734
Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma
Park1, Y; Kim, DS; Jeon, MJ; Lee, BH; Yu, ES; Kang, KW; Lee, SR; Sung, HJ; Nam, MH; Yoon, SY; Choi, CW; Kang, ES; Cho, D; Kim, K; Kim, BS; Kim, DW; Kim, SJ

INT J HEMATOL 2019 10.1007/s12185-019-02693-z
The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores
Huh1, S; Oh, SY; Lee, S; Lee, JH; Kim, SH; Lee, GW; Kim, SJ; Kim, WS; Lee, HS; Jo, JC; Kim, MJ; Kwon, JH; Kim, HJ

CANCER RES TREAT 2019 10.4143/crt.2018.555
Body Cavity- Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma
Shin1, J; Ko, YH; Oh, SY; Yoon, DH; Lee, JO; Kim, JS; Park, Y; Shin, HJ; Kim, SJ; Won, JH; Yoon, SS; Kim, WS; Koh, Y

ANN LAB MED 2019 10.3343/alm.2019.39.5.430
Flow Cytometric Analysis of T Cells in Hemophagocytic Lymphohistiocytosis
Park1, MS; Yoo, IY; Kim, HJ; Kim, SH; Kim, SJ; Cho, D

Cancer Med 2019 10.1002/cam4.2347
Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma
Li Chan1, EH; Koh, LP; Lee, J; De Mel, S; Jeyasekharan, A; Liu, X; Tang, T; Lim, ST; Tao, M; Quek, R; Ras, MFB; Lee, YS; Diong, C; Tan, D; Kim, SJ; Chee, YL; Poon, LM

SCI REP-UK 2019 10.1038/s41598-019-48513-6
Prognostic values of novel biomarkers in patients with AL amyloidosis
Kim1, D; Lee, G; Choi, JO; Kim, K; Kim, S; Ju, ES; Jeon, ES

BIOL BLOOD MARROW TR 2019 10.1016/j.bbmt.2019.03.016
A Phase I/II Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study
Park1, SS; Kim, K; Kim, SJ; Lee, JH; Yoon, SS; Mun, YC; Lee, JJ; Eom, HS; Kim, JS; Min, CK

LEUKEMIA LYMPHOMA 2019 10.1080/10428194.2019.1573998
Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes
Shin1, SH; Kim, YJ; Lee, D; Cho, D; Ko, YH; Cho, J; Park, WY; Park, D; Kim, SJ; Kim, WS

SCI REP-UK 2019 10.1038/s41598-019-44245-9
Associations of Electrocardiographic Parameters with Left Ventricular Longitudinal Strain and Prognosis in Cardiac Light Chain Amyloidosis
Kim1, D; Lee, GY; Choi, JO; Kim, K; Kim, SJ; Jeon, ES

CANCER RES TREAT 2019 10.4143/crt.2018.191
Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus-Positive and -Negative Relapsed or Refractory Non-Hodgkin Lymphomas
Kim1, SJ; Hyeon, J; Cho, I; Ko, YH; Kim, WS

CANCER RES TREAT 2019 10.4143/crt.2018.190
Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma
Lee1, H; Oh, D; Yang, K; Ko, YH; Ahn, YC; Kim, WS; Kim, SJ

BONE MARROW TRANSPL 2019 10.1038/s41409-018-0253-y
A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing <= 70 kg
Kuruvilla1, J; Tzeng, CH; Cho, SG; Kim, SJ; Tang, JL; Su, YM; Wu, JY; Vargo, R; Cheverton, P

ANN HEMATOL 2019 10.1007/s00277-018-3516-1
Validation of the Marginal Zone Lymphoma International Prognostic Index
Hong1, J; Cho, J; Ko, YH; Kim, SJ; Kim, WS

CYTOKINE 2019 10.1016/j.cyto.2018.10.009
Profiles of serum cytokines and their clinical implications in patients with peripheral T-cell lymphoma
Yi1, JH; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ

LEUKEMIA LYMPHOMA 2019 10.1080/10428194.2018.1480772
Serum IL18 is associated with hemophagocytosis and poor survival in extranodal natural killer/T-cell lymphoma
Lim1, SW; Ryu, KJ; Lee, H; Ko, YH; Kim, WS; Kim, SJ

EUR J NUCL MED MOL I 2018 10.1007/s00259-018-4093-1
A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score
Yhim1, HY; Park, Y; Han, YH; Kim, S; Kang, SR; Moon, JH; Jeong, JH; Shin, HJ; Kim, K; Choi, YS; Kim, K; Kim, MK; Kong, E; Kim, DS; Eo, JS; Lee, JH; Kang, DY; Lee, WS; Lee, SM; Do, YR; Ham, JS; Kim, SJ; Kim, WS; Choi, JY; Yang, DH; Kwak, JY

CANCER SCI 2018 10.1111/cas.13844
Vitamin D deficiency is associated with inferior survival of patients with extranodal natural killer/T-cell lymphoma
Kim1, SJ; Shu, C; Ryu, KJ; Kang, D; Cho, J; Ko, YH; Lee, SY; Guallar, E; Zhao, W; Kim, WS

BIOL BLOOD MARROW TR 2018 10.1016/j.bbmt.2018.07.034
Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation
Jeong1, SH; Song, HN; Park, JS; Yang, DH; Koh, Y; Yoon, SS; Lee, HW; Eom, HS; Won, JH; Kim, WS; Kim, SJ

ANN HEMATOL 2018 10.1007/s00277-018-3442-2
The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms
Hwang1, HS; Yoon, DH; Hong, JY; Park, CS; Lee, YS; Ko, YH; Kim, SJ; Kim, WS; Suh, C; Huh, J

J CLIN MICROBIOL 2018 10.1128/JCM.00438-18
Comparative Evaluation of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in Diagnosis of Latent Tuberculosis Infection in Immunocompromised Patients
Ryu1, MR; Park, MS; Cho, EH; Jung, CW; Kim, K; Kim, SJ; Oh, HY; Huh, W; Jang, HR; Koh, WJ; Park, HY; Kim, YH; Sinn, DH; Choi, JO; Joh, JW; Kim, JM; Kim, SJ; Park, JB; Kang, ES

CANCER RES TREAT 2018 10.4143/crt.2017.207
Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study
Kang1, D; Cho, J; Kim, IR; Kim, MK; Kim, WS; Kim, SJ

ANN HEMATOL 2018 10.1007/s00277-018-3387-5
Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study
Oh1, SY; Kim, WS; Kang, HJ; Lee, JH; Huh, S; Kim, S; Yoon, DH; Hong, JY; Lee, WS; Kim, HJ; Won, JH; Park, BB; Lee, SI; Suh, C

INVEST NEW DRUG 2018 10.1007/s10637-018-0582-0
Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy
Cho1, H; Yoon, DH; Kim, KP; Bae, KS; Kim, WS; Eom, HS; Kim, JS; Hong, JY; Kim, SJ; Lee, H; Kim, SJ; Suh, C

MODERN PATHOL 2018 10.1038/s41379-018-0064-0
Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement
Hyeon1, J; Lee, B; Shin, SH; Yoo, HY; Kim, SJ; Kim, WS; Park, WY; Ko, YH

ANN HEMATOL 2018 10.1007/s00277-018-3313-x
Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma
Cho1, J; Kim, SJ; Park, S; Yoo, KH; Ki, CS; Ko, Y; Kim, WS

ANN HEMATOL 2018 10.1007/s00277-018-3317-6
Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis
Hong1, JY; Yoon, DH; Suh, C; Kim, WS; Kim, SJ; Jo, JC; Kim, JS; Lee, WS; Oh, SY; Park, Y; Kim, SY; Lee, MH; Lee, HS; Do, YR

GENOME RES 2018 10.1101/gr.228080.117
Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data
Fan1, J; Lee, HO; Lee, S; Ryu, DE; Lee, S; Xue, C; Kim, SJ; Kim, K; Barkas, N; Park, PJ; Park, WY; Kharchenko, PV

BONE MARROW TRANSPL 2018 10.1038/s41409-018-0097-5
Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study
Yoo1, KH; Kang, D; Kim, IR; Choi, EK; Kim, JS; Yoon, SS; Lee, CH; Park, S; Kim, SJ; Kim, K; Kim, WS; Jung, CW; Choi, HJ; Jang, JH; Cho, J

ANTICANCER RES 2018 10.21873/anticanres.12679
The Potential of Exosomes Derived from Chronic Myelogenous Leukaemia Cells as a Biomarker
Kang1, KW; Jung, JH; Hur, W; Park, J; Shin, H; Choi, B; Jeong, H; Kim, DS; Yu, ES; Lee, SR; Sung, HJ; Kim, SJ; Choi, CW; Kim, HK; Hong, S; Park, JH; Choi, Y; Park, Y; Kim, BS

BRIT J HAEMATOL 2018 10.1111/bjh.14701
A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System
Jung1, SH; Kim, K; Kim, JS; Kim, SJ; Cheong, JW; Kim, SJ; Ahn, JS; Ahn, SY; Yang, DH; Kim, HJ; Lee, JJ

CANCER SCI 2018 10.1111/cas.13597
Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy
Yamaguchi1, M; Suzuki, R; Kim, SJ; Ko, YH; Oguchi, M; Asano, N; Miyazaki, K; Terui, Y; Kubota, N; Maeda, T; Kobayashi, Y; Amaki, J; Soejima, T; Saito, B; Shimoda, E; Fukuhara, N; Tsukamoto, N; Shimada, K; Choi, I; Utsumi, T; Ejima, Y; Kim, WS; Katayama, N

CANCER RES TREAT 2018 10.4143/crt.2017.182
Low-Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-Cell
Lee1, GI; Oh, D; Kim, WS; Kim, SJ; Ko, YH; Woo, KI; Kim, YD; Ahn, YC

HUM PATHOL 2018 10.1016/j.humpath.2017.12.006
Identification of T-cell receptor expression in EBV-positive neoplastic cells in extranodal NK/T-cell lymphoma, nasal-type, and comparison with T-cell receptor gene rearrangement by BIOMED-2 assay
Takayama1, T; Shin, S; Kang, S; Kim, SJ; Kim, WS; Ko, YH

PLoS One 2018 10.1371/journal.pone.0192656
Lack of usefulness of computed tomography for surveillance in patients with aggressive non-Hodgkin lymphoma
Kang1, KW; Lee, SR; Kim, DS; Yu, ES; Sung, HJ; Kim, SJ; Choi, CW; Park, Y; Kim, BS

Blood Cancer J 2018 10.1038/s41408-018-0056-9
CXCR4 can induce PI3K delta inhibitor resistance in ABC DLBCL
Kim1, JH; Kim, WS; Ryu, KJ; Kim, SJ; Park, C

ANN ONCOL 2018 10.1093/annonc/mdx684
Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/IINK/T-cell lymphoma
Kwong1, YL; Kim, SJ; Tse, E; Oh, SY; Kwak, JY; Eom, HS; Do, YR; Mun, YC; Lee, SR; Shin, HJ; Suh, C; Chuang, SS; Lee, YS; Lim, ST; Izutsu, K; Suzuki, R; Relander, T; d'Amore, F; Schmitz, N; Jaccard, A; Kim, WS

CANCER RES TREAT 2018 10.4143/crt.2017.091
Validation of the Korean Version of the Quality of Life-Cancer Survivors (QOL-CS-K) Questionnaire in Lymphoma Survivors
Cho1, J; Kang, D; Kim, IR; Kim, WS; Ferrell, B; Kim, SJ

HEMATOL ONCOL 2017 10.1002/hon.2374
Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma
Hong1, JY; Ryu, KJ; Lee, JY; Park, C; Ko, YH; Kim, WS; Kim, SJ

Blood Cancer J 2017 10.1038/s41408-017-0030-y
Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers
Tang1, T; Khoo, LP; Lim, C; Ham, JS; Kim, SJ; Hong, HM; Phipps, C; Lee, YS; Tao, M; Quek, R; Farid, M; Lin, TY; Kim, WS; Lim, ST

HEMATOL ONCOL 2017 10.1002/hon.2374
Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma
Hong1, JY; Ryu, KJ; Lee, JY; Park, C; Ko, YH; Kim, WS; Kim, SJ

JPN J CLIN ONCOL 2017 10.1093/jjco/hyx120
Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy
Park1, JS; Lim, DH; Ahn, YC; Park, W; Kim, SJ; Kim, WS; Kim, K

ONCOTARGET 2017 10.18632/oncotarget.20988
Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma
Hong1, J; Kim, SJ; Chang, MH; Kim, JA; Kwak, JY; Kim, JS; Yoon, DH; Lee, WS; Do, YR; Kang, HJ; Eom, HS; Park, Y; Won, JH; Mun, YC; Kim, HJ; Kwon, JH; Kong, JH; Oh, SY; Lee, S; Bae, SH; Yang, DH; Jun, HJ; Lee, HS; Yun, HJ; Lee, SI; Kim, MK; Yi, JH; Lee, JH; Kim, WS; Suh, C

LANCET INFECT DIS 2017
Mycobacterium abscessus glossitis
Ko1, JH; Kang, CI; Cho, SY; Ha, YE; Lee, NY; Kim, SJ; Chung, DR; Peck, KR; Song, JH

ANN ONCOL 2017 10.1093/annonc/mdx316
Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease
Lim1, SH; Hong, JY; Lim, ST; Hong, H; Arnoud, J; Zhao, W; Yoon, DH; Tang, T; Cho, J; Park, S; Ko, YH; Kim, SJ; Suh, C; Lin, T; Kim, WS

ONCOTARGET 2017 10.18632/oncotarget.19301
Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma
Ham1, JS; Park, HY; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ

KOREAN JOURNAL OF INTERNAL MEDICINE 2017 10.3904/kjim.2015.406
Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea
Kim1, HS; Kim, HJ; Kim, SH; Choi, JY; Ko, YH; Kim, WS; Jung, CW; Kim, SJ

HEMATOL ONCOL 2017 10.1002/hon.2283
Macrophage inflammatory protein 1 alpha (MIP-1) may be associated with poor outcome in patients with extranodal NK/T-cell lymphoma
Kim1, HS; Ryu, KJ; Ko, YH; Kim, HJ; Kim, SH; Kim, WS; Kim, SJ

Leuk Lymphoma. 2017 Jun;58(6):1341-1348. doi: 10.1080/10428194.2016.1236380. Epub 2016 Oct 9.
Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma
Moon SH11, Lee AY1, Kim WS2, Kim SJ2, Cho YS1, Choe YS1, Kim BT1, Lee KH1.

Ann Hematol. 2017 May;96(5):739-747. doi: 10.1007/s00277-017-2940-y. Epub 2017 Feb 9.
Sexual problems in male vs. female non-Hodgkin lymphoma survivors: prevalence, correlates, and associations with health-related quality of life
Kim IR11, Kim SH2, Ok ON3, Kim SH4, Lee S5, Choi E6, Kim SJ7, Yoon DH8, Lee MH9.

Nutrition. 2017 Apr;36:67-71. doi: 10.1016/j.nut.2016.06.009. Epub 2016 Jun 25.
Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma
Kim HS11, Lee JY2, Lim SH2, Cho J3, Kim SJ2, Jang JH2, Kim WS2, Jung CW2, Kim K4.

Blood. 2017 Apr 27;129(17):2437-2442. doi: 10.1182/blood-2016-12-756841. Epub 2017 Feb 10.
PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase
Kwong YL11, Chan TSY1, Tan D2,3, Kim SJ4, Poon LM5, Mow B6, Khong PL7, Loong F8, Au-Yeung R8, Iqbal J9, Phipps C2,3, Tse E1.

Oncotarget. 2017 Mar 7;8(10):17038-17049. doi: 10.18632/oncotarget.14928.
The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP
Jung H11,2, Yoo HY3, Lee SH3, Shin S4, Kim SC1, Lee S1, Joung JG1, Nam JY1,3, Ryu D1,3, Yun JW1,5, Choi JK2, Ghosh A5, Kim KK5, Kim SJ6, Kim WS6, Park WY1, Ko YH4.

Oncotarget. 2017 Mar 28;8(13):22014-22022. doi: 10.18632/oncotarget.15782.
Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm
Yoon N11, Ahn S2, Yong Yoo H3, Jin Kim S4, Seog Kim W4, Hyeh Ko Y5.

Psychooncology. 2017 Mar;26(3):330-336. doi: 10.1002/pon.4136. Epub 2016 Apr 13.
Unmet needs of non-Hodgkin lymphoma survivors in Korea: prevalence, correlates, and associations with health-related quality of life
Kim SH11, Lee S2, Kim SH3, Ok ON4, Kim IR5, Choi E1, Kang YK6, Kim SJ7, Lee MH8.

Bone Marrow Transplant. 2017 Feb;52(2):258-263. doi: 10.1038/bmt.2016.260. Epub 2016 Nov 7.
Predictors of general discomfort, limitations in activities of daily living and intention of a second donation in unrelated hematopoietic stem cell donation
Lee MH11, Jang JH2, Min HJ3, Jang HI2, Nah JH2, Lyu CJ4, Han KS5, Won JH6, Lee YH7, Chong SY8, Mun YC9, Lee WS10, Kim SJ11, Kim I12.

Oncotarget. 2017 Feb 21;8(8):13782-13791. doi: 10.18632/oncotarget.14636.
Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
Hong JY11, Ryu KJ2, Park C3, Hong M4, Ko YH5, Kim WS6, Kim SJ2,6.

ONCOTARGET, JAN 17 2017, 8(3):5361-5370, DOI: 10.18632/oncotarget.14243
Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF-kappa B and Btk
Kim JH1, Kim WS, Hong JY, Ryu KJ, Kim SJ, Park C

Oncotarget. 2017 Jan 10;8(2):2466-2476. doi: 10.18632/oncotarget.13690.
FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma
Ryu KJ11, Park C2, Hong M3, Ko YH4, Kim WS5, Kim SJ1,5.

Cancer Res Treat. 2017 Jan;49(1):92-103. doi: 10.4143/crt.2015.476. Epub 2016 May 9.
Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma
Maeng CH11, Ko YH2, Lim DH3, Kang ES4, Choi JY5, Kim WS6, Kim SJ6,7.

Mod Pathol. 2017 Jan;30(1):4-14. doi: 10.1038/modpathol.2016.56. Epub 2016 Sep 30.
Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression
Son SM11, Ha SY1, Yoo HY2,3, Oh D4, Kim SJ3,5, Kim WS3,5, Ko YH1,3.

Oncotarget. 2016 Dec 20;7(51):85584-85591. doi: 10.18632/oncotarget.11319.
Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL1008)
Yoon DH11, Kim SJ2, Jeong SH3, Shin DY4, Bae SH5, Hong J6, Park SK7, Yhim HY8, Yang DH9, Lee H10, Kang HJ11, Lee MH12, Eom HS10, Kwak JY8, Lee JH6, Suh C1, Kim WS2.

Oncotarget. 2016 Dec 27;7(52):86433-86445. doi: 10.18632/oncotarget.13239.
Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma
Park HY11,2, Lee SB3, Yoo HY4, Kim SJ5, Kim WS5, Kim JI1, Ko YH2.

Ann Oncol. 2016 Nov;27(11):2133-2134. Epub 2016 Aug 8.
Reply to the letter to the editor 'Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma' by Tan et al.
Kim SJ11,2, Kim WS3.

Oncotarget. 2016 Nov 22;7(47):76934-76943. doi: 10.18632/oncotarget.12734.
Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era
Seo S11, Hong JY1, Yoon S1,2, Yoo C1, Park JH1, Lee JB3, Park CS4, Huh J5, Lee Y5, Kim KW6, Ryu JS7, Kim SJ8, Kim WS8, Yoon DH1, Suh C1.

Int J Hematol. 2016 Nov;104(5):591-595. Epub 2016 Jul 25.
Clinical features and treatment outcome of Epstein-Barr virus-positive nodal T-cell lymphoma
Jung KS11,2, Cho SH2, Kim SJ1, Ko YH3, Kim WS4.

Oncotarget. 2016 Nov 1;7(44):72033-72043. doi: 10.18632/oncotarget.12459.
Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study
Kim SJ11, Hong JS2, Chang MH3, Kim JA4, Kwak JY5, Kim JS6, Yoon DH7, Lee WS8, Do YR9, Kang HJ10, Eom HS11, Park Y12, Won JH13, Mun YC14, Kim HJ15, Kwon JH16, Kong JH17, Oh SY18, Lee S19, Bae SH20, Yang DH21, Jun HJ22, Kim YS23, Yun HJ24, Lee SI25, Kim MK26, Park EK27, Kim WS1, Suh C7.

J Infect. 2016 Nov;73(5):496-505. doi: 10.1016/j.jinf.2016.06.011. Epub 2016 Jul 7.
Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients
Park S11, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Chung DR2, Kang CI2, Peck KR2, Jung CW3.

Oncotarget. 2016 Oct 18;7(42):68350-68359. doi: 10.18632/oncotarget.12029.
Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis
Kim SJ11, Shin HT2, Lee HO2, Kim NK2, Yun JW2, Hwang JH3, Kim K1, Park WY2.

Oncotarget. 2016 Sep 13;7(37):59892-59901. doi: 10.18632/oncotarget.10988.
Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation
Park S11, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Jung CW1.

Acta Haematol. 2016;136(3):186-90. doi: 10.1159/000448159. Epub 2016 Sep 14.
Mediastinal Gray Zone Lymphoma with Features Intermediate between Classical Hodgkin Lymphoma and Primary Mediastinal B-Cell Lymphoma
Song HN11, Kim SJ, Ko YH, Kim WS.

BMC Cancer. 2016 Aug 8;16:613. doi: 10.1186/s12885-016-2645-y.
Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen
Jung SH11, Cho MS1, Kim HK2, Kim SJ2, Kim K3, Cheong JW4, Kim SJ4, Kim JS4, Ahn JS1, Kim YK1, Yang DH1, Kim HJ1, Lee JJ5; Korean Multiple Myeloma Working Party (KMMWP).

Oncotarget. 2016 Jul 26;7(30):47127-47133. doi: 10.18632/oncotarget.9478.
Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker
Ryu D11,2, Kim HJ3, Joung JG1, Lee HO1,4, Bae JS1, Kim SJ5, Kim H5, Park WY1,2,4, Kim K5.

Bone Marrow Transplant. 2016 Jun;51(6):807-12. doi: 10.1038/bmt.2016.6. Epub 2016 Feb 8.
Prognostic relevance of pretransplant Deauville score on PET-CT and presence of EBV DNA in patients who underwent autologous stem cell transplantation for ENKTL
Lim SH11, Hyun SH2, Kim HS1, Lee JY1, Yoo KH1, Jung KS1, Song HN1, Cho J1, Park S1, Ko YH3, Kim SJ1, Choi JY2, Kim WS1.

Haematologica. 2016 Jun;101(6):757-63. doi: 10.3324/haematol.2015.139253. Epub 2016 Jan 27.
Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma
Yoo HY11, Kim P2, Kim WS3, Lee SH4, Kim S5, Kang SY6, Jang HY7, Lee JE7, Kim J8, Kim SJ3, Ko YH9, Lee S10.

Leuk Lymphoma. 2016;57(6):1413-22. doi: 10.3109/10428194.2015.1113276. Epub 2015 Dec 24.
CD79B limits response of diffuse large B cell lymphoma to ibrutinib
Kim JH11, Kim WS1,2, Ryu K1, Kim SJ1,2, Park C1.

Haematologica. 2016 Jun;101(6):e271. doi: 10.3324/haematol.2016.148015. Epub 2016 May 31.
Author reply to Comment on: Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma, by Yoo et al.
Yoo HY11, Kim P2, Kim WS3, Lee SH1, Kim S4, Kang SY5, Jang HY6, Lee JE6, Kim J7, Kim SJ3, Ko YH8, Lee S9.

Mod Pathol. 2016 May;29(5):430-43. doi: 10.1038/modpathol.2016.47. Epub 2016 Mar 25.
Nasal-type NK/T-cell lymphomas are more frequently T rather than NK lineage based on T-cell receptor gene, RNA, and protein studies: lineage does not predict clinical behavior
Hong M11,2, Lee T1, Young Kang S1, Kim SJ3, Kim W3, Ko YH1.

Ann Lab Med. 2016 May;36(3):209-14. doi: 10.3343/alm.2016.36.3.209.
Usefulness of Flow Cytometric Analysis for Detecting Leptomeningeal Diseases in Non-Hodgkin Lymphoma
Shin SY11,2, Lee ST2,3, Kim HJ2, Oh YL4, Kim SJ5, Kim WS5, Kim SH6.

Ann Hematol. 2016 May;95(6):911-9. doi: 10.1007/s00277-016-2660-8. Epub 2016 Apr 6.
The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea
Lee HS11, Min CK2, Lee JJ3, Kim K4, Kim SJ4, Yoon DH5, Eom HS6, Lee H6, Lee WS7, Shin HJ8, Lee JH9, Park Y10, Jo JC11, Do YR12, Mun YC13, Lee MH14

Korean J Intern Med. 2016 May;31(3):560-9. doi: 10.3904/kjim.2014.222. Epub 2016 Feb 22.
Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy
Maeng CH11,2, Ahn SW3, Ryu SY3, Han S3, Ko YH4, Ji JH5, Kim WS2, Kim SJ2.

Ann Oncol. 2016 Apr;27(4):712-8. doi: 10.1093/annonc/mdv624. Epub 2016 Feb 8.
A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymph